Zurich, Switzerland, 7th July 2008 - Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combinations for trauma, wound and spinal indications, announced today the appointment of Beat Neukom as Chief Financial Officer with immediate effect. Mr Neukom has over 17 years experience in finance and accounting which was gained in both Europe and the USA, including more than 10 years in the healthcare industry, primarily with the Johnson & Johnson companies.
Prior to joining Kuros, Mr Neukom was Worldwide Finance Director for DePuy Mitek, Johnson & Johnson’s Sports Medicine / Arthroscopy business, one of its fastest growing medical devices companies. Prior to that Mr Neukom was Finance Director of DePuy Spine. During his tenure at Johnson & Johnson Mr Neukom held numerous positions with increasing responsibilities, such as Regional Finance Controller Medical Devices EMEA where he was responsible for the growth in the emerging Eastern European and Russian markets. Before joining Johnson & Johnson he held positions in Project Management for the development and implementation of Cash Management / Treasury as well as other financial systems. Mr Neukom is a Certified Management Accountant (CMA) and holds a Business Administration degree from the University of Applied Science in Zurich / Winterthur, Switzerland.
Didier Cowling, Chief Executive Officer of Kuros, said: “I am delighted to welcome Beat as the new CFO of Kuros. Beat is an excellent executive with strong financial and leadership skills as well as a broad experience of the Life Science industry. Beat is a very strong addition to our senior management team and I am confident he will make a great contribution to the company’s success.”
About Kuros
www.kuros.ch
Kuros is a biotechnology company that is focused on the development of novel biomaterials and bioactive-biomaterial combinations for trauma, wound and spinal indications.
Kuros’ combination products are designed to mimic the body’s natural healing process. The products consist of fusion proteins of naturally occurring bioactive factors, covalently incorporated into fibrin or synthetic matrices. The incorporation of the biologically active molecules into the injectable matrices aims to maximize their activity by retention at the site of action. Kuros products are designed to combine ease of application with localized delivery. Kuros has a number of methodologies to achieve the desired retention and release profiles of the biologically active molecules.
Kuros’ has a diverse pipeline of product candidates with its most advanced products being in trauma and wound care.
Since its creation, Kuros has received over $80 million in funding. The company is located in Zurich, Switzerland.
Press Enquiries
Kuros
Didier Cowling, CEO +41 (0)44 200 56 62
Alistair Irvine, Director of Business Development +41 (0)44 200 56 62
For International Media Enquires:
Citigate Dewe Rogerson
David Dible, Sylvie Berrebi +44 (0)207 638 9571
For Swiss Media Enquires:
The IR Firm
Martin Meier-Pfister +41 (0)43 244 81 40
Jan Gregor +41 (0)43 244 81 54
